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HIV‑exposed uninfected infants: elevated 
cord blood Interleukin 8 (IL‑8) is significantly 
associated with maternal HIV infection 
and systemic IL‑8 in a Kenyan cohort
Barbara Lohman‑Payne1* , Benjamin Gabriel1, Sangshin Park2,3, Dalton Wamalwa4, 
Elizabeth Maleche‑Obimbo4, Carey Farquhar5,6,7, Rose Kerubo Bosire8,9 and Grace John‑Stewart5,6,7,10
Abstract 
Background: In low and middle income countries, human immunodeficiency virus (HIV) exposed, uninfected 
(HEU) infants demonstrate higher morbidity and mortality than their unexposed counterparts. To determine possible 
immune correlates of this effect, we investigated the impact of in utero HIV exposure on the uninfected neonatal 
immune milieu and maternal factors mediating these abnormalities in a cohort of vaginally delivered mother‑infants. 
Samples of delivery and cord blood plasma were selected from 22 Kenyan HIV‑infected women and their HIV exposed 
uninfected (HEU) infants drawn from the pre‑ARV era, while 19 Kenyan HIV‑uninfected (HU) women and their infants 
were selected from a control cohort.
Results: Compared to HU cord plasma, HEU cord plasma contained significantly higher levels of pro‑inflammatory 
cytokines interleukins (IL)‑6 and ‑8 (both p < 0.001) and significantly lower levels of CXC motif chemokine 11 (CXC11) 
(p < 0.001). Mediation analysis demonstrated that maternal HIV infection status was a significant determinant of infant 
IL‑8 responses: HEU status was associated with a ninefold higher infant:mother (cord:delivery) plasma levels of IL‑8 
(p < 0.005), whereas maternal viral load was negatively associated with HEU IL‑8 levels (p = 0.04) and not associated 
with HEU IL‑6 levels.
Conclusions: Exposure to maternal HIV infection drives an increase in prenatal IL‑8 that is partially mediated by 
maternal cytokine levels. Differences between maternal and infant cytokine levels strongly suggest independent 
modulation in utero, consistent with prenatal immune activation. Elevated pro‑inflammatory signals at birth may 
interfere with T cell responses at birth and subsequently influence immune maturation and the risk of morbidity and 
mortality in HEU infants.
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Background
Successful implementation of global programs for the 
prevention of mother-to-child transmission (PMTCT) 
of HIV has decreased perinatal HIV infections from 
500,000 to 15,000 cases per year worldwide in the last 
decade (UNAIDS, 2015). However, it is now evident that 
this has created a large and expanding number of HIV 
exposed but uninfected (HEU) infants. These infants 
experience increased rates of morbidity and mortality 
compared with their HIV unexposed (HU) counterparts. 
A recent meta analysis of 22 studies from low and mid-
dle income countries showed a 70% increase in mortality 
among HEU during the first 2  years of life, and several 
individual studies report a 3- to fourfold increase in mor-
tality over HU [1, 2].
The preponderance of current evidence suggests that 
the immune systems of HEU children differ in fundamen-
tal ways from HU children including changes in the num-
bers and proportions of leukocyte subsets present from 
the first months of life [3–5]. At birth cord blood T cells 
from HEU children can mount HIV-1 specific responses, 
indicating exposure to circulating maternal HIV antigen 
[6, 7]. In response to a range of stimuli, HEU cord blood 
mononuclear cells (CBMC) produce different cytokine 
profiles and reduced T cell helper responses compared 
to HU CBMC [8, 9]. However, there is controversy in the 
field as to the cause of the observed immune changes in 
HEU infants, the relative contribution of maternal health, 
and relative differences observed in HIV unexposed 
infants from the same communities. It is plausible that 
chronic in utero exposure to the maternal environment 
of persistent HIV infection affects the developing neona-
tal immune system, resulting in the immune alterations 
observed at birth. Equally plausible is that exposure to 
antiretroviral medications, poor nutrition, or exposure to 
multiple environmental antigens other than HIV, could 
stimulate a similar profile in HIV unexposed infants liv-
ing in similar conditions.
Here we designed a retrospective study using careful 
specimen selection to systematically minimize the above 
factors known or suspected to confound interpretation 
of HEU data. Specifically we drew from specimen and 
data archives established prior to ARV interventions and 
purposefully selected mother-infants pairs with a clini-
cal medical record indicating no infections or hospitali-
zations during the study duration in order to minimize 
the effects of environmental pathogens. Moreover we 
selected HEU infants and HU control infants of similar 
birthweight and gestational age and chose to evaluate 
infant cord blood as a window into prenatal immunity. 
Here we demonstrate cord blood plasma T cell cytokines 
and chemokines from HIV uninfected infants born 
to HIV infected women not taking ARV are markedly 
different from HIV unexposed infants. HIV positive 
maternal T cell cytokines were markedly lower than HIV 
uninfected women at delivery, and despite this, HEU 
cord plasma contained significantly elevated levels of the 
pro-inflammatory and chemotactic cytokines IL-6 and 
IL-8 and reduced levels of an interferon gamma (IFN-γ)-
induced chemokine, CXCL11 compared to HU infants.
Methods
Cohort and specimen selection
This study used specimens from two cohort studies. 
Cohort 1 was a randomized controlled trial conducted 
1992–1998 in Nairobi, Kenya prior to the availability of 
antiretrovirals for prevention of mother-to-child-trans-
mission, as previously described [10]. HIV seropositive 
women were enrolled during pregnancy, and provided 
written informed consent for participation in the study 
and storage of specimens. Maternal peripheral blood 
was collected when women presented at the hospital at 
onset of delivery. Maternal plasma HIV-1 RNA levels at 
delivery were determined using a transcription-mediated 
amplification (TMA) method sensitive for the detection 
of multiple HIV subtypes (Gen-probe HIV-1 viral load 
assay) [11]. We selected samples from the HIV infected 
cohort based on proportional representation across quar-
tiles of maternal HIV viral load, as a surrogate for levels 
of fetal exposure to HIV. Infants were examined and cord 
blood was collected at birth. Infants were tested quarterly 
for HIV-1 using HIV-1 PCR filter paper assays [12]. All 
infants selected for the current study were HIV-1 anti-
body negative at 24 months of age.
Cohort 2 enrolled HIV uninfected women between 
2004 and 2006, as previously described [13]. The infection 
status of women enrolled in the HIV uninfected cohort 
was verified by two HIV-1 rapid tests (determine HIV-1/
HIV-2 antibody/HIV-1 antigen test, Abbott Laboratories, 
Abbott Park, IL and Unigold HIV-1 antibody test, Trin-
ity Biotech, Bray, Ireland). Women were recruited during 
pregnancy and provided written informed consent for 
participation and storage of specimens. Maternal periph-
eral blood was collected at delivery and infants were 
examined and cord blood collected at birth.
Women/infant pairs from both cohorts were selected to 
reduce factors suspected of influencing infant immunity: 
lack of history of sexually transmitted infection (STI), not 
currently receiving treatment for an STI, HIV uninfected 
singleton infant, normal birth-weight > 2500  g, and nor-
mal gestational age > 37  weeks, as defined in the parent 
study [10]. All specimen collection was conducted within 
the guidelines of the Declaration of Helsinki and all com-
ponents of this study were approved by the Kenyatta 
National Hospital Ethics and Research Committee and 
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the Institutional Review Boards (IRB) of the University of 
Washington and the University of Rhode Island.
Detection of plasma cytokines
Peripheral and cord blood plasma was separated from 
EDTA-anticoagulated blood at the time of delivery and 
stored frozen at − 80  °C. We analyzed duplicate plasma 
samples for levels of interleukins (IL)-1β, IL-2, IL-4, 
IL-5, IL-6, IL-7, IL-8 (also known as CXCL8), IL-10, 
IL-12(p70), IL-13, IL-17A, IL-21 and IL-23, interferon 
(IFN)-γ, tumor necrosis factor (TNF)-α, granulocyte/
macrophage-colony stimulatory factor (GM-CSF), as 
well as chemokines CCL3, CCL4, CCL20, CXCL11 
and CX3CL1 using a multiplexed high sensitivity 
human T-cell cytokine magnetic bead panel (EMD Mil-
lipore Corp., Billerica, MA, USA). Three independ-
ent plates were run with standard- and plate-controls; 
women-infant pairs were grouped per plate. Assays 
were conducted in accordance with the manufacturer’s 
instructions. All cytokine values below the lower limit of 
detection were recoded as the lower limit of detection of 
individual cytokine standards.
Statistical analysis
Cytokine data were tested for outliers and reported as 
medians and interquartile ranges. Medians of related 
samples were compared using Wilcoxon rank sum test 
and independent sample medians were compared using 
Mann–Whitney U. The cohort size for paired samples 
of HIV-infected women at delivery and their infant cord 
blood was 22, while the cohort size for HIV uninfected 
women at delivery and their infant cord blood was 19. In 
unpaired analyses, data from an additional 8 HEU cord 
blood specimens were included. Linear regression was 
used for analysis of cord blood IL-8 and viral load. Bon-
ferroni correction for multiple comparisons was applied 
to multiplexed cytokine data.
Mediation analyses using structural equation modeling 
(SEM) [14, 15] were conducted to determine whether all, 
or part, of the relationship between maternal HIV status 
(infected/uninfected) and cord blood cytokine levels was 
explained by maternal cytokine levels. Mediation analy-
ses were also performed to determine whether mater-
nal cytokine levels mediated the relationship between 
maternal viral load and infant cord blood cytokines. Data 
were natural log transformed for mediation analysis. Sta-
tistical analyses were performed using Prism (version 
6.0f, GraphPad, La Jolla, CA) and SAS 9.4 software (SAS 
Institute, Cary, NC). A p value < 0.05 was considered to 




The HIV-1-infected women selected for this sub-study 
were representative of the original HIV cohort as young, 
moderately immunosuppressed, without a medical his-
tory of HIV-related illnesses. Specifically, the median 
age at enrolment was 25 years (interquartile range (IQR), 
23–28). The women had a median CD4+ T cell count of 
403 cells/ml (IQR, 313–523) and CD4:CD8 ratio of 0.44 
(IQR, 0.29–0.73). Nineteen percent of the HIV posi-
tive women had a CD4:CD8 ratio greater than 1.0. The 
median viral load at delivery was 4.6  log10 RNA copies/
ml plasma (IQR, 4.4–5.1). The HIV uninfected mother-
infant cohort was enrolled from a similar community. 
The median age at enrolment was 25 years (IQR, 23–29). 
Infants born to HIV infected and HIV uninfected groups 
of women were of similar birth-weight: 3.3 kg (IQR, 3.0–
3.6) vs 3.1 kg (IQR 2.9–3.5), respectively.
HIV‑infected women have increased IL‑8 at delivery 
compared to HIV‑uninfected women
The infant’s nascent leukocyte responses occur in the 
presence of ‘pre-conditioned’ prenatal cytokine milieu, 
based on maternal–fetal exposures. We chose to evaluate 
maternal delivery specimens as a reflection of prenatal 
and early life exposures. All pregnant women regard-
less of HIV status presented at delivery with detectable 
pregnancy-supporting cytokines IL-4 and -10, although 
the HIV-infected women had significantly lower levels of 
IL-4 (14 pg/ml (IQR, 8–19) vs 136 pg/ml (IQR, 84–164) 
and IL-10 (5  pg/ml (IQR, 4–9 vs 19  pg/ml IQR, 8–23, 
p < 0.001, respectively), compared to HIV-uninfected 
women (Table 1).
Unsurprising for a population of women with chronic 
untreated HIV and a median CD4 of ~ 400 cells/ml, the 
HIV-infected women had significantly lower levels of 14 
of the 21 T cells cytokines across the broad range of func-
tions including pro-inflammatory, chemotactic, immu-
noregulatory, and Th2 type cytokines compared to HIV 
uninfected women. Interestingly, IL-8 was detected at a 
significantly higher level compared to HIV-uninfected 
women; HIV-infected women had a fourfold increase in 
levels of plasma cytokine IL-8 at delivery compared to 
uninfected women (36  pg/ml (IQR 15–361) vs 9  pg/ml 
(IQR 8–13) p < 0.001, respectively).
Infants differing by HIV exposure status in utero: HEU 
infants are born with significantly increased levels of IL‑6 
and ‑8 and decreased levels of CXCL11 compared to HU 
infants
Of 21 T cell cytokines/chemokines measured, 15 were 
present at median concentrations above the lowest limit 
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of detection (Table  2). Pro-inflammatory cytokines IL-6 
and -23 were significantly different in HEU vs HU cord 
blood samples. Median IL-6 levels were ~ 25-fold higher 
in HEU infants compared to HU infants (24 pg/ml (IQR 
2–155), vs 1  pg/ml (IQR 1–6), respectively). Levels of 
IL-23 were undetectable in the HEU infant cord blood; 
a subset of HU infant cord blood samples had detectable 
levels sufficient for the group medians to be significantly 
different (p < 0.001). Chemotactic cytokines IL-8 and 
CXCL11 were significantly different in cord blood plasma 
from infants exposed to HIV in utero (both p < 0.001). 
Median cord blood plasma IL-8 levels were > 50-fold 
higher in HEU infants compared to HU infants.
(748  pg/ml (IQR, 93–1882) vs. 13  pg/ml (IQR 7–26), 
respectively). CXCL11 was present at
significantly lower levels in HEU cord blood plasma 
compared to HU cord plasma (p < 0.001). CXCL11, also 
known as Interferon-inducible T-cell alpha chemotac-
tic (ITAC) and Interferon-γ-inducible protein 9 (IP9), 
was present at approximately half the levels found in 
HU infants (154 pg/ml (IQR 65–254) vs 372 pg/ml (IQR 
279–428)), while well above the lower limit of detec-
tion of 1.5  pg/ml). Immunoregulatory cytokine IL-21 
and Th2 cytokine IL-5 levels were significantly differ-
ent in cord blood plasma from HEU infants compared 
to HU infants although of note many individual’s IL-21 
and IL-5 cord blood levels were at or near the limit of 
detection. The remaining cytokines tested were not 
significantly different between HEU and HU (IL-7, 
CX3CL1, CCL3, GM-CSF, IL-10, CCL20, IL-1β, CCL4, 
TNF-α) or were below the lower limit of detection in 
both populations (IFNγ, IL-12(p70), IL-13, IL-17α, IL-2 
and IL-4).
Table 1 Maternal plasma mediators at delivery from HIV-uninfected and HIV-infected women
Bonferroni correction for multiple comparisons was applied; thus p < 0.003 was considered significant
LLD lower limit of test kit detection, pg/ml
a Number women with plasma samples available at time of delivery
b Independent sample medians were compared using Mann–Whitney U test
Mediator, pg/ml LLD HIV uninfected  na = 19 HIV infected n = 22 p  valueb
Median (IQR) Median (IQR)
Pro‑inflammatory
 IL‑23 8.0 194 (151–408) 53 (29–103) < 0.001
 IL‑17α 0.7 7 (5–12) 2 (1–4) < 0.001
 IL‑12(p70) 0.5 5 (4–8) 2 (1–2) < 0.001
 TNF‑α 0.4 8 (7–10) 6 (5–7) < 0.001
 IL‑1β 0.5 5 (5–7) 2 (1–5) 0.25
 IL‑6 0.2 9 (6–30) 6 (2–40) 0.25
Chemotactic
 IL‑8/CXCL8 0.3 9 (8–13) 36 (15–361) < 0.001
 CX3CL1 18.0 333 (205–459) 71 (48–120) < 0.001
 CCL20 0.6 22 (19–27) 15 (13–20) < 0.002
 CXCL11 1.5 157 (93–236) 45 (24–85) < 0.001
 CCL3 0.3 30 (25–34) 13 (10–57) 0.25
 CCL4 1.0 33 (27–46) 13 (7–56) 0.02
Immunoregulatory
 IFN‑γ 0.6 21 (17–32) 12 (11–17) < 0.001
 IL‑7 0.4 14 (10–18) 7 (5–10) < 0.001
 IL‑2 0.5 0 (0–5) 2 (1–3) 0.09
 IL‑21 0.3 3 (1–5) 2 (1–4) 1.0
Th2
 IL‑4 1.8 136 (84–162) 14 (8‑19) < 0.001
 IL‑5 0.5 4 (2–5) 2 (1‑2) < 0.001
 IL‑10 1.5 19 (8–23) 5 (4‑9) < 0.001
 GM‑CSF 1.2 282 (132–358) 37 (21‑51) < 0.001
 IL‑13 0.3 10 (5–16) 5 (4‑8) 0.01
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Cord blood plasma IL‑8 and CXCL11 levels are increased 
compared to maternal delivery plasma
We conducted paired analyses of cytokine levels pre-
sent in cord plasma relative to levels in maternal 
plasma collected at delivery for the 23 HEU and 19 
HU mother-infant dyads (Fig.  1). Median (IQR) HEU 
cord blood IL-8 concentration was significantly higher 
than that measured in maternal delivery blood plasma 
(748 pg/ml, (IQR 93–1882) vs 36 pg/ml (IQR 15–361); 
p < 0.001), suggestive of synthesis within the infant 
circulation rather than passive transfer across the pla-
centa. Median (IQR) HEU cord IL-6 levels were not 
significantly higher than HIV + maternal blood plasma 
levels (24  pg/ml (IQR 2–155) vs 6  pg/ml (IQR 2–40), 
p = 0.019), while HU infants had lower cord blood IL-6 
concentrations than their HIV uninfected mothers 
(1 pg/ml (IQR 1–6) vs 9 pg/ml (IQR 6–30), p = 0.001). 
Similarly, median (IQR) HEU cord IL-21 was lower and 
levels did not reach significance when compared to 
paired maternal delivery samples (0.7  pg/ml (0.4–2.2) 
vs 2.0  pg/ml (1.1–3.6); p = 0.014). A different pattern 
was observed for Th2 cytokine IL-5, which was largely 
undetectable in cord blood plasma collected from 
HEU infants and present at significantly lower levels 
compared with cord blood from HU infants (0.5 pg/ml, 
(0.5–0.5) vs (0.6 pg/ml (0.5–0.9), respectively).
The lower levels of CXCL11 and IL-23 observed in 
HEU relative to HU cord blood plasma were not due 
to lower maternal levels at delivery. Similar to our 
observation with IL-8, median (IQR) HEU cord blood 
levels of CXCL11 were significantly higher than mater-
nal delivery blood plasma (153 pg/ml (IQR 65–254) vs 
45 pg/ml (IQR 24–85) p < 0.001). In contrast, all individ-
ual HEU cord blood levels of IL-23 were below the limit 
of detection, while readily detectable in HIV + maternal 
plasma (53 pg/ml, (IQR 29–103). The data demonstrate 
cord blood mediators are not uniformly concentrated 
or diluted in infant cord blood, supporting a biologic 
mechanism mediating the observed difference in HEU 
cord blood as compared to a change in maternal–fetal 
vascular permeability.
HIV exposure significantly alters pro‑inflammatory 
cytokines present in cord blood compared to delivery 
blood
The process of delivery is dynamic and to reflect the 
physiologic range that exists for cytokines present in 
maternal and infant circulations at delivery and birth 
Table 2 Infant cord blood plasma mediators from HIV-Unexposed infants compared to HIV-exposed uninfected infants
The following cytokines were below the assay limit of detection in both populations: IFNγ, IL‑12(p70), IL‑13, IL‑17α, IL‑2 and IL‑4
LLD lower limit of test kit detection, pg/ml
a Number samples with valid results
b Bonferroni correction for multiple comparisons was applied; p < 0.003 was considered significant
Mediator, pg/ml LLD HIV unexposed (HU) HIV exposed uninfected (HEU) pb
na Median (IQR) na Median (IQR)
Pro‑inflammatory
 IL‑6 0.2 17 1 (1–6) 29 24 (2–155) 0.001
 IL‑23 8.0 16 8 (8–16) 30 8 (8–8) 0.001
 IL‑1β 0.5 18 4 (1–39) 28 7 (0.5–102) 0.800
 TNF‑α 0.4 19 18 (15–26) 30 15 (9–38) 0.300
Chemotactic
 IL‑8/CXCL8 0.3 19 13 (7–26) 29 748 (93–1882) < 0.001
 CXCL11 1.5 19 372 (279–428) 30 154 (65–254) < 0.0001
 CCL3 0.3 19 34 (17–70) 30 176 (29–1901) 0.030
 CCL4 1.0 19 67 (61–121) 22 71 (290–152) 0.600
 CCL20 0.6 19 40 (27–57) 26 47 (32–133) 0.100
 CX3CL1 18.0 17 18 (18–28) 30 18 (18–18) 0.006
Immunoregulatory
 IL‑21 0.2 15 0.2 (0.2–0.2) 30 0.7 (0.3–2.2) 0.001
 IL‑7 0.4 19 6 (2–13) 30 2 (0.4–4) 0.003
Th2
 IL‑5 0.5 17 0.6 (0.5–0.9) 30 0.5 (0.5–0.5) < 0.0001
 IL‑10 1.5 16 1.5 (1.5–7) 29 3 (1.5–6) 0.100
 GM‑CSF 1.2 19 7 (3–13) 30 5 (1.2–17) 0.700
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we determined a group median index from individual 
mother-infant pairs. An index > 1 indicates the cytokine 
level in cord blood exceeds the level measured in the 
infant’s mother’s delivery plasma.
HIV uninfected women and their unexposed infants 
tended to have an index at or < 1 meaning maternal 
cytokines levels in blood at delivery were greater or equal 
to cord blood levels for IL-6, IL-8, IL-10, CCL3, GM-CSF, 
IL-1β, CCL20 and IL-7 (Fig.  2). HEU cord blood/deliv-
ery cytokine indices were significantly greater than HU 
indices for 7 of 11 detectable cytokines: IL-6, IL-8, IL-10, 
CCL3, GM-CSF, CCL20, and CCL4 (closed vs open cir-
cles, p < 0.005). Several cytokines levels were not signifi-
cantly different in cord blood relative to delivery blood 
in HIV-infected women/HEU infants compared to HIV-
uninfected women and their HU infants: IL-1β, IL-7, 
TNFα, and CXCL11.
Maternal HIV infection, but not viral load, drives infant 
cord blood IL‑8 levels
Statistical modeling with structural equation media-
tion (SEM) is a powerful statistical approach to address 
interdependent relationships among multiple variables 
simultaneously and allows delineation of the relative 
importance of factors within the direct causal pathway 
on the outcome of interest [14, 15]. SEM was used to 
estimate the effect of maternal HIV infection work-
ing through maternal cytokine levels on infant cord 
blood cytokine levels. Maternal HIV infection status 
had a large significant total combined effect on both 
infant cord blood IL-6 and -8 levels (p < 0.001, Fig. 3). 
Maternal HIV infection did not mediate its effect on 
cord blood IL-6 through maternal plasma IL-6 levels 
(p = 0.8), indicating maternal HIV infection affects 
levels of infant cord blood IL-6 through pathways 
not measured in this study (Fig.  3a). However, mater-
nal plasma IL-8 levels contributed 23% of cord blood 
IL-8 levels, a substantial percent for complex biologi-
cal systems, while maternal HIV infection itself medi-
ated 77% of the IL-8 present in cord blood through 
unmeasured pathways (Fig.  3b). Maternal HIV status 
had a significant but very small effect on cord blood 
IL-21; this cytokine was not included in subsequent 
models (total effect β = 0.02, p = 0.002).
We hypothesized maternal viral load as a proxy for 
stimulation of prenatal pro-inflammatory cytokines 
directly. As shown in Fig.  4, the level of cord blood 
plasma IL-8 was negatively correlated with mater-
nal viral load with a low correlation coefficient and a 
marginal p value (slope = − 0.006,  r2 = 0.14, p = 0.04). 
Additionally, SEM with maternal viral load and IL-8 in 
the pathway for mediation of infant cord blood IL-8, 
revealed no significant effect of maternal viral load. 
Taken together these data do not support the hypoth-
esis that maternal viral load directly stimulates infant 
IL-8 production; alternatively, the negative slope, weak 
 r2 value and lack of significance in the SEM models 
indicate factors beyond viral load explain the pattern 
of HEU IL-8 levels at birth.
Discussion
We hypothesized that maternal HIV, either directly via 
viral load/viral antigens or indirectly via altered plasma 
cytokines, would set a different immune stage for HEU 
infants than for HU infants. IL-6 and IL-8 levels present 
in cord blood of HEU infants were significantly elevated 
compared both to their HIV-infected mothers and to 
their HIV-unexposed community peers. Our study pro-
vides a direct link between maternal HIV infection and 
elevated levels of prenatal IL-6 and IL-8 measured in cord 
blood from infants who were born HIV uninfected and 
who did not acquire HIV through vaginal delivery and 
breastfeeding during the first year of life and who were 
unexposed to ARV. Our models demonstrate maternal 
IL-8 directly mediated ~ 25% of the effect of HIV infec-
tion on cord blood IL-8, with ~ 75% of the effect unmeas-
ured in this study, indicative of alternative pathways or 
cellular sources of neonatal IL-8 induction and regula-
tion. In contrast, maternal HIV infection did not medi-
ate infant IL-6 levels via maternal IL-6, leaving all of the 
effect of maternal HIV infection on neonatal IL-6 induc-
tion unexplained in our models.
We have extended the finding that IL-8 is not limited 
to placental transfer in healthy women to that of HIV-
infected-HEU mother-infant pairs [16, 17]. IL-8 is a 
major T cell effector in newborns and can be produced 
by endothelial cells, tissue macrophages, and cells of 
monocytic origin [18]. The IL-8 detected in cord blood 
here is plausibly derived from maternal or infant origin: 
Fig. 1 HIV exposed uninfected infant cord blood displays elevated cytokines consistent with inflammation and immune stimulation compared 
to HIV unexposed infant cord blood. Cytokines were detected in samples from all maternal delivery plasma and infant cord blood plasma using 
multiplexed Luminex Elisa bead‑based technology. Assays at or below the lower limit of detection were assigned the lowest limit of detection. 
Individual plasma concentration (ln pg/ml), group median and IQR are plotted. Related sample medians (HEU vs HIV+ mother, n = 23 pairs; HU vs 
HIV− mother, n = 19 pairs) were compared using Wilcoxon Rank Sum test while independent medians were compared using Mann–Whitney U test 
(HEU vs HU). Symbols are as follows: HIV− women filled squares, HU infants open squares, HEU infants open circles, HIV+ women filled circles
(See figure on next page.)
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Fig. 2 HIV infection associated with changes in delivery and birth cytokine patterns. Cytokines were detected in samples from all maternal delivery 
plasma and infant cord blood plasma using multiplexed Luminex Elisa bead‑based technology and grouped by broad category. Assays at or 
below the lower limit of detection were assigned the lowest limit of detection. Cytokines undetectable in the majority of HEU or HU samples were 
not included: IL‑5, IL‑21, IL‑23 and CX3CL1. The ratio of infant cord blood to maternal delivery blood plasma cytokine levels was calculated. Each 
cytokine ratio is plotted for HU infant‑HIV negative mother (open circles) and HEU infant‑HIV‑infected mother (closed circles) and the fold change 
from the HU group median is indicated. Independent group medians were compared using Mann–Whitney U test with correction for multiple 
comparisons p < 0.005. Significant mediators are bolded
Fig. 3 Maternal HIV infection drives infant IL‑6 and IL‑8 levels present at birth in HEU infants through different pathways. SEM models with maternal 
HIV infection (yes/no), maternal IL‑8 levels at delivery in the pathway, and infant cord blood IL‑8 levels as the outcome variable for 42 mother‑infant 
pairs. HEU infants have 2.38 ln IL‑6 levels in cord blood at birth and none of the infant IL‑6 is attributable to maternal IL‑6 levels (a). HEU infants have 
3.75 times ln IL‑8 levels in cord blood than detected in HU cord blood, and ~ 23% of this can be attributed to the maternal IL‑8 levels (b)
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from viral antigen-stimulated endothelial cells lining the 
umbilical cord, tissue macrophages present in the syncy-
tiotrophoblast layer of the placenta or monocytic cells of 
infant ontogeny [19].
The onset of active labor and vaginal delivery is asso-
ciated with elevated levels of IL-6 in both maternal and 
infant circulation [20], however we recorded a ~ 50-fold 
increase in the IL-6 index of cord blood to delivery blood 
observed in HEU compared to HU mother-infant pairs, 
the biggest difference amongst the mediators meas-
ured. Infection and inflammation during pregnancy are 
hypothesized to be associated with induction of placental 
cytokines, including IL-6, and increased fetal exposure to 
pro-inflammatory cytokines can result in increased risk 
of infant neurologic injury, even in the absence of HIV 
[21]. In addition to maternal infection/inflammation, 
direct transfer of microbes secondary to HIV infection 
may occur from the maternal bloodstream across the pla-
centa into the fetal circulation, such as has been observed 
with increased gut microbial translocation [22]. Alterna-
tively direct or indirect microbial LPS stimulation may 
induce placental cytokine production and the release or 
production of downstream mediators following Toll-like 
receptor signalling [23].
The elevated levels of IL-8 we observed in HEU but 
not in HU cord blood could result from a combination 
of increased production or decreased down-regulation of 
IL-8. As part of the pro-inflammatory antiviral immune 
response, intracellular regulators of IL-8 include IFN-γ, a 
cytokine notably present at low levels in newborns [24, 
25]. Thus newborns with low levels of IFN-γ might be 
unable to down-regulate IL-8. Additionally, HIV tat has 
been shown to signal production of IL-8 [26], and ongo-
ing genital tract viral replication during pregnancy could 
result in placental HIV tat. Prolonged exposure of fetal 
and neonatal T lymphocytes to elevated IL-8 likely leads 
to intracellular signaling of gene pathways associated 
with cell survival, proliferation, and metabolism [27]. 
Hypothetically, neutrophils and other granulocytes pro-
grammed to respond to IL-8 along a chemotactic gradi-
ent also might be unable to respond to the signals if there 
is no functional gradient present, disabling the intended 
effect of chemotaxis and instead resulting in an immune 
‘confusion’ or ‘paralysis’ until levels of circulating IL-8/
IL-6 return to homeostasis. The consequence of a lack of 
recruitment of neutrophils to the sites of tissue damage 
and infection is consistent with clinical descriptions of 
HEU morbidity and mortality.
Our analyses demonstrated a consistent pattern of sig-
nificantly increased levels of chemotactic cytokines pre-
sent in cord blood compared to delivery blood in HEU 
infants compared to HU infants (Fig.  2). The increased 
relative concentrations of IL-8, CCL3, CCL4, CCL20 in 
HEU circulation compared to maternal circulation sug-
gests a coordinated response to inflammatory signaling. 
GM-CSF, although present at levels below that found in 
maternal circulation, is significantly increased in HEU 
compared to HU infants. IL-10 levels are increased in 
HEU infants, although still lower than levels found in 
maternal circulation. IL-10 is in part regulated by IL-6 
levels, thus it is feasible higher circulating IL-6 lev-
els release the inhibition on IL-10 production in HEU 
infants. Regardless the source of mediators detected 
in HEU cord blood, the finding of significantly elevated 
cytokines compared to both HIV unexposed control cord 
blood plasma as well as paired maternal blood collected 
at delivery suggests controlled HIV infection during 
pregnancy drives the fetal immune response.
This study had several strengths. Access to stored 
specimens from the pre-ARV era allowed us to elimi-
nate the direct and indirect effect of ARVs on maternal 
and neonatal cytokine production. Longitudinal HIV 
testing within the parent cohorts allows us to rule out 
individuals with subsequent acquisition of HIV. While 
the inclusion of Kenyan HIV-uninfected mother-infant 
dyads is a strength of the study, allowing us to examine 
cytokine responses in populations of women living in 
similar socio-economic conditions, it raises a potential 
weakness considering the time difference in collection 
of samples from the two cohorts. Further research is 
needed to determine the cellular source of the elevated 
IL-8 and the mechanism of induction/or release from 
negative feedback for production of this cytokines. 
Additionally, because we selected normal birthweight 
Fig. 4 Linear regression of HEU infant cord blood IL‑8 levels by 
maternal HIV at delivery. The impact of maternal HIV RNA copies/
ml plasma on HEU plasma IL‑8 concentrations was determined 
using linear regression. HIV RNA copies were determined using TMA 
method; IL‑8 levels were determined using multiplexed ELISA format, 
both as described in methods. A negative linear association between 
maternal viral load and infant IL‑8 concentrations at birth is shown by 
the dashed line, slope = − 0.0055
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and gestational age infants for both HEU and HU 
infants, we cannot assess the role of maternal and fetal 
systemic inflammation on birth anthropometry.
The majority of immune function studies of HEU 
compared to HU infants have evaluated cellular 
responsiveness following antigenic stimulation in vitro. 
Our studies focused on the prenatal cytokine environ-
ment in which presumably the cellular response would 
arise. In a study of plasma cytokines from HEU and HU 
infants born to HIV+ ARV-treated and healthy HIV− 
pregnant Brazilian women, HEU and HU cord blood 
plasma IL-8 levels were low and similar in HEU infants 
delivered via Caesarian section compared to HU infants 
delivered vaginally [28]. It remains an important public 
health goal to identify the effects of chronic maternal 
infections on fetal and infant immunity, correlations 
with infant health, and response to maternal antiviral 
treatments.
Conclusions
We conclude that in utero stimuli stemming from 
infection generated an immune profile consistent with 
fetal/infant immune activation, particularly cytokines 
associated with macrophage activation, above what 
is expected at parturition. The weak association with 
maternal viral load raises the concern that HEU infants 
exposed to ARV may still be at risk for increased altered 
immune profile at birth.
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